Heme-binding-mediated negative regulation of the tryptophan metabolic enzyme indoleamine 2,3-dioxygenase 1 (IDO1) by IDO2

Experimental and Molecular Medicine

Volumn 46, Issue 11, 2014, Pages

  Lee, Young Kwan ^a   Lee, Hoon Bok ^a   Shin, Dong Mi ^b   Kang, Min Jueng ^c   Yi, Eugene C ^c   Noh, Seungjoo ^a   Lee, Jaewoo ^a   Lee, Chulbom ^a   Min, Chang Ki ^d   Choi, Eun Young ^a  

^a Seoul National University   (South Korea)

^b Seoul National University   (South Korea)

^c Seoul National University   (South Korea)

^d The Catholic University of Korea   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; HEME; HISTIDINE; INDOLEAMINE 2,3 DIOXYGENASE; INDOLEAMINE 2,3 DIOXYGENASE 1; INDOLEAMINE 2,3 DIOXYGENASE 2; UNCLASSIFIED DRUG; INDOLEAMINE 2,3-DIOXYGENASE 1, HUMAN; INDOLEAMINE 2,3-DIOXYGENASE 2, HUMAN; PROTEIN BINDING; TRYPTOPHAN;

AMINO ACID METABOLISM; AMINO ACID SUBSTITUTION; APOPTOSIS; ARTICLE; BINDING SITE; CATALYSIS; CELL CYCLE; CELL DEATH; CELL GROWTH; CELL SURVIVAL; CONTROLLED STUDY; HEK293 CELL LINE; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; PROTEOMICS; TRYPTOPHAN METABOLISM; CELL PROLIFERATION; GENE EXPRESSION; GENETICS; METABOLISM; UPREGULATION;

CELL PROLIFERATION; CELL SURVIVAL; GENE EXPRESSION; HEK293 CELLS; HEME; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; PROTEIN BINDING; TRYPTOPHAN; UP-REGULATION;

EID: 84927745557     PISSN: 12263613     EISSN: 20926413     Source Type: Journal    
DOI: 10.1038/emm.2014.69     Document Type: Article

References (39)

1. Murray MF. The human indoleamine 2,3-dioxygenase gene and related human genes. Curr Drug Metab 2007; 8: 197-200.
2. Metz R, Duhadaway JB, Kamasani U, Laury-Kleintop L, Muller AJ, Prendergast GC. Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan. Cancer Res 2007; 67: 7082-7087.
3. Munn DH, Sharma MD, Lee JR, Jhaver KG, Johnson TS, Keskin DB et al. Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science 2002; 297: 1867-1870.
4. Prendergast GC. Immune escape as a fundamental trait of cancer: Focus on IDO. Oncogene 2008; 27: 3889-3900.
5. Fukunaga M, Yamamoto Y, Kawasoe M, Arioka Y, Murakami Y, Hoshi M et al. Studies on tissue and cellular distribution of indoleamine 2,3-dioxygenase 2: The absence of IDO1 upregulates IDO2 expression in the epididymis. J Histochem Cytochem 2012; 60: 854-860.
6. Shimizu T, Nomiyama S, Hirata F, Hayaishi O. Indoleamine 2,3-dioxygenase. Purification and some properties. J Biol Chem 1978; 253: 4700-4706.
7. Mellor AL, Munn DH. IDO expression by dendritic cells: Tolerance and tryptophan catabolism. Nat Rev Immunol 2004; 4: 762-774.
8. Tone S, Takikawa O, Habara-Ohkubo A, Kadoya A, Yoshida R, Kido R. Primary structure of human indoleamine 2,3-dioxygenase deduced from the nucleotide sequence of its cDNA. Nucleic Acids Res 1990; 18: 367.
9. Dai X, Zhu BT. Indoleamine 2,3-dioxygenase tissue distribution and cellular localization in mice: Implications for its biological functions. J Histochem Cytochem 2010; 58: 17-28.
10. Hansen AM, Driussi C, Turner V, Takikawa O, Hunt NH. Tissue distribution of indoleamine 2,3-dioxygenase in normal and malaria-infected tissue. Redox Rep 2000; 5: 112-115.
11. Munn DH. Indoleamine 2,3-dioxygenase, tumor-induced tolerance and counter-regulation. Curr Opin Immunol 2006; 18: 220-225.
12. Moretti S, Menicali E, Voce P, Morelli S, Cantarelli S, Sponziello M et al. Indoleamine 2,3-dioxygenase 1 (IDO1) is up-regulated in thyroid carcinoma and drives the development of an immunosuppressant tumor microenvironment. J Clin Endocrinol Metab 2014; 99: E832-E840.
13. Friberg M, Jennings R, Alsarraj M, Dessureault S, Cantor A, Extermann M et al. Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection. Int J Cancer 2002; 101: 151-155.
14. Thaker AI, Rao MS, Bishnupuri KS, Kerr TA, Foster L, Marinshaw JM et al. IDO1 metabolites activate beta-catenin signaling to promote cancer cell proliferation and colon tumorigenesis in mice. Gastroenterology 2013; 145 (416-425): E411-e414.
15. Ino K, Yoshida N, Kajiyama H, Shibata K, Yamamoto E, Kidokoro K et al. Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer. Br J Cancer 2006; 95: 1555-1561.
16. Ball HJ, Sanchez-Perez A, Weiser S, Austin CJ, Astelbauer F, Miu J et al. Characterization of an indoleamine 2,3-dioxygenase-like protein found in humans and mice. Gene 2007; 396: 203-213.
17. Witkiewicz AK, Costantino CL, Metz R, Muller AJ, Prendergast GC, Yeo CJ et al. Genotyping and expression analysis of IDO2 in human pancreatic cancer: A novel, active target. J Am Coll Surg 2009; 208: 781-787.
18. Lob S, Konigsrainer A, Zieker D, Brücher BL, Rammensee HG, Opelz G et al. IDO1 and IDO2 are expressed in human tumors: Levo- but not dextro- 1-methyl tryptophan inhibits tryptophan catabolism. Cancer Immunol Immunother 2009; 58: 153-157.
19. Lob S, Konigsrainer A, Schafer R, Rammensee HG, Opelz G, Terness P. Levo- but not dextro-1-methyl tryptophan abrogates the IDO activity of human dendritic cells. Blood 2008; 111: 2152-2154.
20. Liu X, Shin N, Koblish HK, Yang G, Wang Q, Wang K et al. Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity. Blood 2010; 115: 3520-3530.
21. Qian F, Villella J, Wallace PK, Mhawech-Fauceglia P, Tario JD Jr, Andrews C et al. Efficacy of levo-1-methyl tryptophan and dextro-1-methyl tryptophan in reversing indoleamine-2,3-dioxygenase-mediated arrest of T-cell proliferation in human epithelial ovarian cancer. Cancer Res 2009; 69: 5498-5504.
22. Merlo LM, Pigott E, DuHadaway JB, Grabler S, Metz R, Prendergast GC et al. IDO2 is a critical mediator of autoantibody production and inflammatory pathogenesis in a mouse model of autoimmune arthritis. J Immunol 2014; 192: 2082-2090.
23. Metz R, Smith C, DuHadaway JB, Chandler P, Baban B, Merlo LM et al. IDO2 is critical for IDO1-mediated T-cell regulation and exerts a nonredundant function in inflammation. Int Immunol 2014; 26: 357-367.
24. Kim JH, Lee SR, Li LH, Park HJ, Park JH, Lee KY et al. High cleavage efficiency of a 2A peptide derived from porcine teschovirus-1 in human cell lines, zebrafish and mice. PLoS ONE 2011; 6: E18556.
25. Samikkannu T, Saiyed ZM, Rao KV, Babu DK, Rodriguez JW, Papuashvili MN et al. Differential regulation of indoleamine-2,3-dioxygenase (IDO) by HIV type 1 clade B and C Tat protein. AIDS Res Hum Retroviruses 2009; 25: 329-335.
26. Ross PL, Huang YN, Marchese JN, Williamson B, Parker K, Hattan S et al. Multiplexed protein quantitation in Saccharomyces cerevisiae using aminereactive isobaric tagging reagents. Mol Cell Proteomics 2004; 3: 1154-1169.
27. Arai M, Imai H, Koumura T, Yoshida M, Emoto K, Umeda M et al. Mitochondrial phospholipid hydroperoxide glutathione peroxidase plays a major role in preventing oxidative injury to cells. J Biol Chem 1999; 274: 4924-4933.
28. Anderson KM, Berrebi-Bertrand I, Kirkpatrick RB, McQueney MS, Underwood DC, Rouanet S et al. cDNA sequence and characterization of the gene that encodes human myotrophin/V-1 protein, a mediator of cardiac hypertrophy. J Mol Cell Cardiol 1999; 31: 705-719.
29. Paull TT, Rogakou EP, Yamazaki V, Kirchgessner CU, Gellert M, Bonner WM. A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage. Curr Biol 2000; 10: 886-895.
30. Nemeth MJ, Cline AP, Anderson SM, Garrett-Beal LJ, Bodine DM. Hmgb3 deficiency deregulates proliferation and differentiation of common lymphoid and myeloid progenitors. Blood 2005; 105: 627-634.
31. Broxmeyer HE, Kappes F, Mor-Vaknin N, Legendre M, Kinzfogl J, Cooper S et al. DEK regulates hematopoietic stem engraftment and progenitor cell proliferation. Stem Cells Dev 2012; 21: 1449-1454.
32. Zhang Z, Zhang R. Proteasome activator PA28 gamma regulates p53 by enhancing its MDM2-mediated degradation. EMBO J 2008; 27: 852-864.
33. Brinkmann U, Brinkmann E, Gallo M, Pastan I. Cloning and characterization of a cellular apoptosis susceptibility gene, the human homologue to the yeast chromosome segregation gene CSE1. Proc Natl Acad Sci USA 1995; 92: 10427-10431.
34. Pallotta MT, Orabona C, Volpi C, Vacca C, Belladonna ML, Bianchi R et al. Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells. Nat Immunol 2011; 12: 870-878.
35. Orabona C, Pallotta MT, Grohmann U. Different partners, opposite outcomes: A new perspective of the immunobiology of indoleamine 2,3- dioxygenase. Mol Med 2012; 18: 834-842.
36. Littlejohn TK, Takikawa O, Truscott RJ, Walker MJ. Asp274 and his346 are essential for heme binding and catalytic function of human indoleamine 2,3-dioxygenase. J Biol Chem 2003; 278: 29525-29531.
37. Sugimoto H, Oda S, Otsuki T, Hino T, Yoshida T, Shiro Y. Crystal structure of human indoleamine 2,3-dioxygenase: Catalytic mechanism of O2 incorporation by a heme-containing dioxygenase. Proc Natl Acad Sci USA 2006; 103: 2611-2616.
38. Takikawa O, Kuroiwa T, Yamazaki F, Kido R. Mechanism of interferongamma action. Characterization of indoleamine 2,3-dioxygenase in cultured human cells induced by interferon-gamma and evaluation of the enzymemediated tryptophan degradation in its anticellular activity. J Biol Chem 1988; 263: 2041-2048.
39. Hou DY, Muller AJ, Sharma MD, DuHadaway J, Banerjee T, Johnson M et al. Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res 2007; 67: 792-801.